The 2014 Euro Health Consumer Index
27 January 2015 | By Health Consumer Powerhouse
In spite of financial crisis, European healthcare keeps improving – but the equity gap widens...
List view / Grid view
News
Moberg Pharma’s fungal nail product approved in China
27 January 2015 | By Moberg Pharma
Moberg Pharma AB announced that its partner, Menarini Asia-Pacific, has received approval for Moberg’s fungal nail product in China...
New Cetraben® 3-in-1 emollient expands UK treatment options for people with dry skin conditions
26 January 2015 | By Pegasus
Research shows 87% of users prefer Cetraben® Ointment compared with other widely prescribed ointments...
New Additions to IONICON Trace Gas Analyzer Series to be showcased at Pittcon 2015
26 January 2015 | By IONICON
A fast GC add-on for PTR-TOFMS trace gas analyzers and the new PTR-QiTOF are now available...
Doctors fear that new health tech is turning UK into a nation of “worried well”
26 January 2015 | By Lukats and Shapiro
Doctors fear the wealth of health data from the internet and smartphones could be creating a new army of “worried well”, a survey for the Astellas Innovation DebateTM shows...
Santen receives a positive CHMP opinion for EU marketing authorization for Ikervis®
26 January 2015 | By NewCap.
Santen SAS announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending the granting of a marketing authorization for Ikervis®...
Alliance Pharma appoints Nigel Clifford as an independent Non-Executive Director
26 January 2015 | By Alliance Pharma plc
Alliance Pharma plc has appointed Nigel Clifford as an independent Non-Executive Director of the Company. Nigel will join the Board with immediate effect.
Novartis drug Jakavi® recommended by CHMP for EU approval to treat adults with rare blood cancer polycythemia vera
23 January 2015 | By Novartis
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Jakavi® (ruxolitinib) for the treatment of adult patients with polycythemia vera (PV) who are resistant to or intolerant of hydroxyurea...
Major milestone for GSK/NIH candidate Ebola vaccine as first doses shipped to Liberia for use in phase III clinical trial
23 January 2015 | By GlaxoSmithKline
GSK has announced that the first batch of its candidate Ebola vaccine is being shipped to west Africa...
Treatment market for Irritable Bowel Syndrome could hit $1.5 billion by 2023, says GlobalData
22 January 2015 | By GlobalData
The global therapeutics market for Irritable Bowel Syndrome (IBS) is set to rise in value from $589.6 million in 2013 to $1.5 billion by 2023, representing a high Compound Annual Growth Rate (CAGR) of almost 9.9%, says research and consulting firm GlobalData...
CAMO Software exhibiting at IFPAC 2015
CAMO Software will be exhibiting at the IFPAC® Annual Meeting in Arlington, VA (Washington D.C.) January 25-28. CAMO Software can be found in booth #709...
Sunesis Pharmaceuticals selects Quotient Clinical’s real-time adaptive manufacturing to support its vosaroxin clinical mass balance/ADME program
21 January 2015 | By kdm communications
Quotient Clinical, the Translational Pharmaceutics® Company, and Sunesis Pharmaceuticals have announced the initiation of a clinical mass balance/ADME trial for vosaroxin – a candidate therapeutic for acute myelogenous leukemia (AML)...
Once daily treatment option made available for up to one million adult Britons with type 2 diabetes and moderate chronic kidney disease
21 January 2015 | By Aurora
A once daily injection has been approved for adults with type 2 diabetes and moderate renal impairment (stage 3 chronic kidney disease) in the UK...
Pharmalink announces an Open Investigational New Drug (IND) application for Nefecon®
21 January 2015 | By Citigate Dewe Rogerson
Pharmalink AB, a specialty pharma company focused on orphan and niche products, announces that its IND for Nefecon® is now open with the US Food & Drug Administration...
Bristol-Myers Squibb appoints Giovanni Caforio, M.D., Chief Executive Officer, effective May 5; Lamberto Andreotti to become Chairman
21 January 2015 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced a number of leadership changes approved by its board of directors and effective at the close of the annual Shareholders’ Meeting on May 5...
